Register by Friday, June 15 to Save $400
Advancements in the application of imaging techniques such as quantitative HRCT to inform and enrich clinical trials decisions undoubtedly goes hand-in-hand with the next generation of IPF drug development. Leveraging imaging’s capacity to advance biomarker identification, endpoint design and patient identification is now pivotal in advancing clinical translation and drug trial success.
Join your peers to discuss and evaluate:
Mary Salvatore, Associate Professor of Radiology, Mount Sinai Medical Center
Poor prognosis, varying and unpredictable rates of progression despite treatment, and increasing population size means that the need for truly disease modifying IPF candidates is increasing. Is the answer precision therapy?
Harnessing an improved understanding of the genetic mechanisms driving IPF pathologies could offer insights into next generation, better clinical outcomes.
Be part of the discussion at this workshop on:
Timothy Blackwell, Professor of Cell & Developmental Biology, Vanderbilt University Medical Center
Jonathan Kropski, Assistant Professor of Medicine, Vanderbilt University Medical Center